Veracyte Announces Fourth Quarter and Full-Year 2015 Financial Results, Provides 2016 Financial Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Leerink Partners Remains Bullish as Low Operating Expenses Drives Veracyte's (VCYT) EPS Beat
March 11, 2016 10:02 AM ESTLeerink Partners maintained an Outperform rating on Veracyte, Inc (NASDAQ: VCYT), and cut the price target to $8.00 (from $11.00), following the company's 4Q earnings report. VCYT reported Q4 revenue of $14M, below consensus of $14.3M. Also, Q4 loss per shares of ($0.29) was better than consensus... More
Veracyte (VCYT) Tops Q4 EPS by 1c
March 10, 2016 4:36 PM ESTVeracyte (NASDAQ: VCYT) reported Q4 EPS of ($0.29), $0.01 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $14 million versus the consensus estimate of $14.45 million.
GUIDANCE:
Veracyte sees FY2016 revenue of $59-63 million, versus the consensus of $62.9... More
